The algorithms that we have developed and are continually improving provide tools in which to identify novel biomarkers which form the basis for signatures or fingerprints that when applied to mass spectrometry data sets of patient samples have transformed the Imvac business opportunity to service and contract discovery model in the name of CompanDX.

CompanDX brings together leading-edge mass analytical techniques with artificial neural networks to deliver unique capabilities in service provision to the pharmaceutical, biotechnology, health care, and academic sectors.

CompanDX delivers unparalleled services ranging from patient stratification in the form of molecular classification of disease subtypes, predictive biomarker signatures for drug response, and prognostic biomarker panels for the prediction of outcomes during clinical trials.